研究单位：[1]Shanghai Pharmaceuticals Holding Co., Ltd[2]The Second Hospital of Anhui Medical University,Hefei,Anhui,China[3]Beijing Anzhen Hospital，Capital Medical University,Beijing,China[4]Beijing Tiantan Hospital，Capital Medical University,Beijing,China[5]Beijing Tongren Hospital,Beijing,China[6]Peking Union Medical College Hospital,Beijing,China[7]Beijing Tsinghua Changgeng Hospital,Beijin,China[8]Xiangya Hospital Central South University,Changsha,China[9]Sichuan Provincial People''s Hospital,Chengdu,China[10]West China Hospital of Sichuan University,Chengdu,China[11]The Second Affiliated Hospital of Hainan Medical University,Haikou,China[12]Qilu Hospital of Shandong University,Jinan,China[13]The First Affiliated Hospital of Shandong First Medical University,Jinan,China[14]Ningbo Huamei Hospital, University of the Chinese Academy of Sciences,Ningbo,China[15]Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine,Shanghai,China[16]Sheng Jing Hospital of China Medical University,Shenyang,China[17]The First Affiliated Hospital of China Medical University,Shenyang,China[18]The Seventh Affiliated Hospital，Sun Yat-sen University,Shenzhen,China[19]Second Hospital of Shanxi Medical University,Taiyuan,China[20]Union Hospital Tongji Medical College Huazhong University of Science and Technology,Wuhan,China[21]The First Affiliated Hospital of Xi''an Jiaotong University,Xi''an,China
研究目的：
To preliminarily evaluate the efficacy and safety of the renin inhibitor (SPH3127 tablets) in reduction in proteinuria in patients with diabetic kidney disease with valsartan as the comparator, and determine the recommended dose.
